Chinese Clinical Oncology

Scope & Guideline

Transforming the landscape of cancer treatment and research.

Introduction

Immerse yourself in the scholarly insights of Chinese Clinical Oncology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2304-3865
PublisherAME PUBLISHING COMPANY
Support Open AccessNo
CountryHong Kong
TypeJournal
Convergefrom 2012 to 2024
AbbreviationCHIN CLIN ONCOL / Chin. Clin. Oncol.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressFLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA

Aims and Scopes

Chinese Clinical Oncology focuses on advancing the understanding of cancer diagnosis, treatment, and management through a multidisciplinary approach. The journal emphasizes the integration of innovative research methodologies and clinical practices to enhance patient outcomes.
  1. Oncology Research and Treatment Innovations:
    The journal emphasizes groundbreaking research in oncology, including novel therapeutic strategies such as immunotherapy, targeted therapies, and advancements in surgical techniques.
  2. Clinical Case Studies and Reviews:
    It publishes detailed case reports and narrative reviews that provide insights into rare cancers, treatment challenges, and emerging clinical practices.
  3. Biomarkers and Genetic Studies:
    Research on biomarkers for cancer diagnosis, prognosis, and treatment response is a core focus, contributing to personalized medicine in oncology.
  4. Multidisciplinary Approaches:
    The journal encourages collaboration across various specialties, including surgery, radiology, and pathology, to address complex cancer cases and improve treatment paradigms.
  5. Health Systems and Policy in Oncology:
    It also explores the impact of healthcare policies and economic factors on cancer treatment accessibility and patient outcomes.
Recent publications in Chinese Clinical Oncology have revealed several emerging themes that reflect the journal's evolving focus and the dynamic landscape of cancer research.
  1. Artificial Intelligence in Oncology:
    There is a growing trend towards integrating artificial intelligence and machine learning in oncology, particularly for improving diagnostic accuracy and treatment personalization.
  2. Immunotherapy and Combination Therapies:
    Research on immunotherapy continues to gain momentum, especially studies exploring combination therapies that enhance treatment efficacy for various cancer types.
  3. 3D Printing and Surgical Innovations:
    The application of 3D printing technology in surgical planning and execution is emerging as a significant area of interest, reflecting advancements in minimally invasive surgical techniques.
  4. Patient-Centered Approaches and Quality of Life:
    An increasing focus on patient-reported outcomes and quality of life assessments in cancer treatment strategies highlights the importance of holistic care.
  5. Genetic and Biomarker Research:
    There is an uptick in studies aimed at identifying genetic markers and biomarker profiles that can guide personalized treatment approaches in oncology.

Declining or Waning

While the journal continues to explore a wide range of oncology topics, certain areas appear to be diminishing in focus based on recent publications.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in publications focused solely on traditional chemotherapy regimens, as the emphasis shifts towards personalized and targeted treatment strategies.
  2. Basic Science and Laboratory Research:
    Research papers centered on basic science and laboratory findings are appearing less frequently, indicating a trend towards clinical and translational research.
  3. Palliative Care Studies:
    Although still important, studies specifically addressing palliative care strategies have decreased, possibly due to a growing focus on curative and innovative treatment methods.

Similar Journals

Expert Review of Anticancer Therapy

Elevating oncology insights through expert reviews.
Publisher: TAYLOR & FRANCIS LTDISSN: 1473-7140Frequency: 12 issues/year

Expert Review of Anticancer Therapy, published by Taylor & Francis Ltd, is a distinguished journal focusing on the dynamic and ever-evolving field of oncology and pharmacology. Since its inception in 2001, this journal has played a pivotal role in disseminating critical reviews and analyses of novel anticancer therapies, fostering a deeper understanding among researchers and practitioners alike. With an impressive categorization in the 2023 Q2 quartiles for both Oncology and Pharmacology, it ranks #98 out of 272 in Pharmacology and #165 out of 404 in Oncology according to Scopus metrics, placing it well within the upper echelons of academic journals. The journal’s rigorous peer-review process ensures high-quality publications that are integral for advancing cancer research and therapeutic strategies. Although currently not an open access journal, it aims to bridge the gap between scientific discovery and clinical application, making it an essential resource for anyone involved in the fight against cancer.

ANNALS OF ONCOLOGY

Innovating therapies for a brighter tomorrow.
Publisher: ELSEVIERISSN: 0923-7534Frequency: 12 issues/year

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.

Tumori Journal

Exploring New Frontiers in Cancer Treatment and Research.
Publisher: SAGE PUBLICATIONS LTDISSN: 0300-8916Frequency: 6 issues/year

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

Surgical Oncology Clinics of North America

Advancing the Frontiers of Surgical Oncology
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 1055-3207Frequency: 4 issues/year

Surgical Oncology Clinics of North America, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of surgical oncology and surgery, captivating readers since its inception in 1995. With ISSN 1055-3207 and E-ISSN 1558-5042, this esteemed journal offers a comprehensive platform for the dissemination of cutting-edge research, clinical studies, and expert reviews pertaining to surgical techniques and oncological advancements. The journal currently holds a commendable Q3 ranking in Oncology and a Q2 ranking in Surgery, underpinned by its impressive Scopus rankings that place it in the top 25% of its category in Medicine, particularly in the surgical domain (Rank #137/551). Although it does not operate under an open-access model, the insights shared within its pages are invaluable for researchers, healthcare professionals, and students dedicated to enhancing patient outcomes in surgical oncology. With a commitment to advancing medical knowledge, Surgical Oncology Clinics of North America remains a crucial resource for those pursuing excellence in surgical practices and oncology treatment methodologies.

npj Precision Oncology

Unlocking Insights for Precision Medicine
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Precision Oncology, an esteemed peer-reviewed journal published by NATURE PORTFOLIO, stands at the forefront of oncological research and precision medicine. Launched as an Open Access platform in 2017, this journal not only facilitates the dissemination of innovative research findings but also ensures that crucial insights are freely accessible to the global scientific community. With an impressive ranking of Q1 in both Cancer Research and Oncology, and a commendable Scopus rank that places it in the top 15% of its field, npj Precision Oncology is dedicated to advancing our understanding of personalized cancer therapies through high-quality research. Catering to professionals, researchers, and students alike, this journal aims to bridge the gap between laboratory science and clinical application, paving the way for transformative approaches in oncology. As the landscape of cancer treatment evolves, npj Precision Oncology remains a crucial platform for fostering collaboration and sparking ideas that can significantly impact patient care.

Rare Tumors

Connecting researchers to combat rare tumors.
Publisher: SAGE PUBLICATIONS LTDISSN: 2036-3605Frequency: 1 issue/year

Rare Tumors, published by SAGE Publications Ltd, is a premier open-access journal dedicated to advancing the understanding and research of rare neoplasms. With the ISSN 2036-3605 and E-ISSN 2036-3613, this journal provides a vital platform for sharing innovative research findings and clinical insights since its inception in 2009. Situated in Italy, Rare Tumors has a converged publication timeline from 2010 to 2024 and aims to foster a supportive community for researchers and professionals in the oncology and histology fields. It has achieved a notable Q3 ranking in Oncology and Q4 in Histology as of 2023, reflecting its crucial role in bridging the knowledge gap in these specialized areas. Despite its relatively humble Scopus ranks, the journal's open-access model ensures that vital information reaches a broad audience, including those in academia, clinical practice, and beyond. It aspires to not only document rare tumor cases but also stimulate dialogue on their diagnosis, treatment, and management strategies, making it an indispensable resource for anyone dedicated to tackling the challenges posed by rare tumors.

Molecular and Clinical Oncology

Advancing cancer research for a healthier tomorrow.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Chinese Journal of Cancer Research

Empowering researchers to combat cancer effectively.
Publisher: CHINESE JOURNAL CANCER RESEARCH COISSN: 1000-9604Frequency: 4 issues/year

Chinese Journal of Cancer Research, published by Chinese Journal Cancer Research Co, is a pivotal platform for disseminating significant findings in the field of oncology. Since its inception in 1988, the journal has provided a comprehensive forum for cancer research, featuring peer-reviewed articles that cover various aspects of cancer biology, prevention, diagnosis, and treatment. Although the journal's coverage is currently discontinued in Scopus and holds an HIndex that has not been specified, it is ranked in the 65th percentile in Medicine - Oncology and the 48th percentile in Biochemistry, Genetics and Molecular Biology - Cancer Research. This reflects its commitment to maintaining quality and relevance in the rapidly evolving field of cancer research. Researchers, professionals, and students are encouraged to explore its rich archive of studies and breakthroughs to enhance their understanding and further their research. For access, the publication remains instrumental for those invested in advancing the global fight against cancer.

Case Reports in Oncology

Empowering Progress in Oncology Research
Publisher: KARGERISSN: 1662-6575Frequency: 3 issues/year

Case Reports in Oncology is a peer-reviewed journal published by KARGER, dedicated to the dissemination of high-quality case studies and clinical reports in the field of oncology. Since its transition to Open Access in 2008, this Swiss-based journal has aimed to broaden the accessibility of key findings to a global audience of researchers, healthcare professionals, and students. The journal is positioned in the Q3 quartile for oncology, indicating its valuable contribution to the field, while also holding a Scopus rank of 294 out of 404 in Medicine, with a percentile of 27%. However, its open access model ensures that even those outside of traditional academic institutions can engage with critical advancements and novel insights from the oncology community. With a publication span extending from 2010 to 2024, Case Reports in Oncology serves as a crucial platform for sharing unique clinical experiences and innovative treatment strategies, ultimately enriching the practice and study of oncology.

Translational Oncology

Transforming Cancer Insights into Clinical Solutions
Publisher: ELSEVIER SCIENCE INCISSN: 1936-5233Frequency: 6 issues/year

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.